Cambridge Healthtech Institute’s Inaugural

Emerging Indications and Modalities
( 新適應症與模態 )

中樞神經系統疾病與罕見疾病、基因與細胞療法、纖維症與肝病領域的進步

2020年6月2日~4日


Significant progress in the fields of genetics, protein science, and drug discovery is driving a renewed interest in emerging indications outside of oncology, and important indications, such as CNS, rare diseases, fibrosis and liver disease. Moreover, new and exciting technologies, such as cell, gene, and gene-edited therapies are offering a new way of treating previously untreatable diseases, and are quickly advancing through the clinic.

CHI's Emerging Indications and Modalities conference provides a platform for pharma, biotech, and academia to discuss and benchmark the latest advances in developing new drug targets and novel therapies across the fields of neuroscience, rare diseases, fibrosis and liver diseases, as well as the unique challenges facing cell and gene therapy development. How do your drug discovery and translational strategies compare?

Final Agenda

Recommended Short Course*

SC4: Optimizing Drug Metabolism, Drug Clearance and Drug-Drug Interactions

*Separate registration required.

6月2日 (二)

10:00 am Main Conference Registration OpeN

MATCHING THE RIGHT MODALITY TO THE RIGHT MECHANISM

11:15 Chairperson’s Remarks

Dario Doller, PhD, Director, Medicinal Chemistry, Sunovion Pharmaceuticals

11:25 Matching the Right Modality to the Right Mechanism for the Right Patient

Julie Chen, PhD, Chemical and Structural Biology Lead, Eisai Center for Genetics Guided Dementia Discovery (G2D2)

11:55 Small Molecule Treatment of Brain Diseases: A Perspective on the Path Forward, Looking Up from the Bottom

Dario Doller, PhD, Director, Medicinal Chemistry, Sunovion Pharmaceuticals

This presentation will analyze and discuss the key challenges facing CNS drug discovery and development, including: where we have been, contemporary neuroscience pipelines, success in CNS drug research, context, contrast and expectations, and where to now?

12:25 pm Leveraging the Power of Human Genetics to Go beyond A-Beta and Tau

Janna Hutz, PhD, Head, Data Sciences, Eisai Center for Genetics Guided Dementia Discovery (G2D2)

12:55 Transition to Lunch

1:00 Luncheon Presentation (Sponsorship Opportunity Available) or Enjoy Lunch on Your Own

1:30 Session Break

CNS DRUG DEVELOPMENT AND TRANSLATION

2:00 Chairperson’s Remarks

Dario Doller, PhD, Director, Medicinal Chemistry, Sunovion Pharmaceuticals

2:05 Machine Learning Models in CNS Drug Discovery and Penetrating the BBB

Istvan Enyedy, PhD, Principal Scientist, Medicinal Chemistry, Biogen

The design of therapeutic agents that penetrate the blood-brain barrier is challenging mainly due to the promiscuity of efflux transporters. The structures of P-gp and BCRP have been published allowing us to build machine learning models that combine the transporter structural information with traditional ligand-based descriptors. The performance of these models will be presented.

2:35 PET Imaging of Neuroinflammation in Neurodegenerative Diseases

Changning Wang, PhD, Assistant Professor of Radiology, Athinoula A. Martinos Center for Biomedical Imaging, Massachusetts General Hospital, Harvard Medical School

Molecular imaging, such as PET, has been widely used in medical research and drug discovery. We have developed new imaging tools and applied them in clinical research and drug discovery. In this presentation, I will discuss the development and application of molecular neuroimaging techniques for brain research. Our work is a unique example on the multidisciplinary research, including molecular imaging, medicinal chemistry, clinical research and preclinical drug discovery.

3:05 A Neuroinflammatory Translational Pipeline for Neurodegenerative Diseases

Jonathan Levenson, PhD, Vice President, Translational Biology, Tiaki Therapeutics

Neuroinflammation is a pathological hallmark of CNS degenerative diseases, yet preclinical translational tools to support drug discovery programs are lacking. Tiaki has developed an ex vivo slice culture and an animal model that manifests a neuroinflammatory state that is aligned with Alzheimer’s and Huntington’s disease. Using these tools, a novel anti-inflammatory target for neurodegenerative disease, which was identified using curated human data, has been progressed to lead optimization.

3:35 Sponsored Presentation (Opportunity Available)

4:05 Networking Refreshment Break and Transition to Keynote


PLENARY KEYNOTE SESSION

4:25 - 6:05

Driving Entrepreneurial Innovation to Accelerate Therapeutic Discoveries

The life sciences community has an unprecedented scientific arsenal to discovery, develop and implement treatments, cures and preventions that enhance human healthcare.

Moderator: Nadeem Sarwar, President, Eisai Center for Genetics Guided Dementia Discovery (G2D2), Eisai Inc.

Panelists: Anthony Philippakis, Chief Data Officer, Broad Institute; Venture Partner, GV

Barbara Sosnowski, Vice President and Global Head, Emerging Science & Innovation Leads, WWRDM, Pfizer

John Hallinan, Chief Business Officer, Massachusetts Biotechnology Council

6:05 Welcome Reception in the Exhibit Hall with Poster Viewing

7:10 Close of Day

6月3日 (三)

7:30 am Registration Open and Morning Coffee

GENE THERAPIES FOR NEUROLOGICAL DISEASEs

8:10 Chairperson’s Remarks

Dario Doller, PhD, Director, Medicinal Chemistry, Sunovion Pharmaceuticals

8:15 Gene Therapy Development for Neurological Diseases

Gabriele Proetzel, PhD, Director, External Neuroscience Innovation, Neuroscience Drug Discovery Unit, Takeda Pharmaceuticals

With the approval of Zolgensma, gene therapy for neurological disorders have become a reality. This presentation will discuss the recent advances for in vivo gene therapy development for the neuronal diseases with their challenges and opportunities. The focus will be on adeno-associated virus (AAV), key aspects for preclinical development and how this is different from classical drug discovery. Discussed will be payload options, delivery, and preclinical models critical for advancing gene therapy into the clinic and to the patient.

8:45 Preclinical Development of an Intrathecally-Administered ASO to Treat Spinal Muscular Atrophy

Kenneth S. Loveday, PhD, DABT, Principal Investigator, Preclinical Safety, Biogen

Patients with spinal muscular atrophy have a defect in the SMN1 gene. Nusinersen is an ASO designed to increase production of SMN protein from the SMN2 gene by modifying splicing of pre-mRNA. Toxicology studies in monkeys used intrathecal dosing to deliver nusinersen across the blood-brain barrier into CSF to its site of action: spinal cord motor neurons. The clinical development program was successful, and initial regulatory approval occurred in December of 2016.

9:15 Tissue Distribution and PK of Antisense Oligonucleotides following Intrathecal Administration

Natasha Penner, PhD, Director, Clinical Pharmacology and Pharmacometrics, Biogen

With oligonucleotides unable to penetrate the blood-brain barrier, this presentation describes tissue distribution and PK of antisense oligonucleotides following intrathecal administration. Nusinersen is an ASO designed to increase production of SMN protein from the SMN2 gene by modifying splicing of pre-mRNA. The clinical development program was successful, and initial regulatory approval occurred in December of 2016.

9:45 Presentation to be Announced

10:00 Sponsored Presentation (Opportunity Available)

10:15 Coffee Break in the Exhibit Hall with Poster Viewing

EMERGING TARGETS AND PATHWAYS

11:00 Lysosomal Dysfunction in Common Neurodegenerative Diseases: From Genetics to the Clinic

Pablo Sardi, PhD, R&D Senior Director, Rare and Neurological Diseases, Sanofi

This presentation will discuss: clinical, genetic and experimental evidence underlies the relevance of lysosomal dysfunction in Parkinson’s disease (PD), and mutations in the lysosomal glucocerebrosidase gene (GBA) accelerate PD progression. First trial has begun testing a GBA pathway modulator in a genetically defined population, and modulation of the lysosomal pathway may also benefit a larger sporadic patient population.

11:30 Targeting Ataxin-2 against TDP43 Pathology Associated with Amyotrophic Lateral Sclerosis and Frontotemporal Dementia

Yinghui Hu, PhD, Associate Principal Scientist, Neurodegeneration Group, Merck

Ataxin-2 has been identified as a potent modifier of TDP43-toxicity. We demonstrated that knockdown of Ataxin-2 or inhibition of Ataxin-2 interaction with TDP43 effectively reversed TDP43-induced toxicity in hu-iPSC neurons. Proteomic analysis was also performed to identify a specific set of proteins associated with the aberrant Ataxin-2/TDP43 interaction. These findings led us to explore various approaches and modalities that can be used as novel strategy for therapeutic intervention.

12:00 pm Sponsored Presentation (Opportunity Available)

12:30 Transition to Lunch

12:35 Luncheon Presentation (Sponsorship Opportunity Available) or Enjoy Lunch on Your Own

1:05 Session Break


PLENARY KEYNOTE SESSION

1:45 - 3:15

Lgr5 Stem Cell-Based Organoids in Human Disease

Hans Clevers, MD, CSO, Director of Research, Princess Máxima Center for Pediatric Oncology, University Medical Center Utrecht; Principal Investigator, Hubrecht Institute for Developmental Biology and Stem Cell Research

Systematically Drugging Ras

Stephen Fesik, PhD, Professor of Biochemistry, Pharmacology, and

Chemistry, Orrin H. Ingram II Chair in Cancer Research, Vanderbilt

University School of Medicine

3:15 Refreshment Break in the Exhibit Hall with Poster Viewing

CELL AND GENE THERAPY

4:00 Chairperson’s Remarks

Dario Doller, PhD, Director, Medicinal Chemistry, Sunovion Pharmaceuticals

4:05 Authentic Cell Therapies for Intractable Neurological Diseases

Stefan Irion, MD, Vice President, Translational Neuroscience, BlueRock Therapeutics

The convergence of cell biology and genetic engineering is creating fundamental new ways to impact disease. Founded in 2016 to capitalize on these technological breakthroughs, we are advancing our novel platform to develop, manufacture, and deliver an entirely new generation of authentic and engineered cell therapies across three therapeutic areas: neurology, cardiology, and immunology. This presentation will focus on cell therapies for intractable neurological diseases.

4:35 Disruption of RNA Metabolism in Neurological Diseases and Emerging Therapeutic Interventions

Matthew Nolan, PhD, Post Doc Research Fellow, Harvard Medical School and Massachusetts General Hospital

RNA binding proteins are critical to the maintenance of the transcriptome via controlled regulation of RNA processing and transport. Alterations of these proteins impact multiple steps of the RNA life cycle resulting in various molecular phenotypes such as aberrant RNA splicing, transport, and stability. Emerging therapeutic approaches to mitigate or reverse alterations of RNA binding proteins in neurological diseases are discussed.

5:05 Find Your Table, Meet Your Moderator

5:10 Roundtable Breakout Discussions

TABLE: Translational Strategies in CNS Drug Development

Moderator: Dario Doller, PhD, Director, Medicinal Chemistry, Sunovion Pharmaceuticals

TABLE: AI and Machine Learning in CNS Drug Development

Moderator: Istvan Enyedy, PhD, Principal Scientist, Medicinal Chemistry, Biogen

TABLE: Modeling Fibrosis

Moderator: Vanessa Morales-Tirado, PhD, Senior Scientist III, Translational Immunology, Immunology Discovery, AbbVie Bioresearch Center

5:45 Reception in the Exhibit Hall with Poster Viewing

6:45 Close of Day

6月4日 (四)

8:00 am Registration Open and Morning Coffee


PLENARY KEYNOTE SESSION

8:30 - 9:40 Applications of Artificial Intelligence in Drug Discovery – Separating Hype from Utility

Patrick Walters, PhD, Senior Vice President, Computation, Relay Therapeutics

9:40 Coffee Break in the Exhibit Hall with Poster Viewing

TARGETING FIBROSIs

10:25 Chairperson’s Remarks

Chairperson to be Announced, Xylyx Bio, Inc.

10:30 Fibrosis Biomarker Tool Kit for the Lung and Beyond

Vanessa Morales-Tirado, PhD, Senior Scientist III, Translational Immunology, Immunology Discovery, AbbVie Bioresearch Center 

Efficient, novel therapeutics against fibrotic diseases are highly desirable. Identification of biomarkers contribute to understanding of disease mechanisms, acceleration of drug development and clinical management. Accessibility to tissues and disease target activities is a challenge in fibrotic diseases such as IPF and scleroderma, highlighting the need for the identification of non-invasive biomarkers to represent drug pharmacodynamics and disease biology. Here, we present novel tools to identify biomarkers in fibrotic diseases.

11:00 Role of Fibroblast Expression of Integrin-Alpha V in Fibrosis and InflammatioN

Kevin Hart, PhD, Principal Scientist, Inflammation, Pfizer Inc. 

Since some integrins can serve as master regulators of fibrosis, we investigated if integrin-alpha V is critical during polarized inflammatory responses during tissue damage disease models. While data confirmed a role for integrin-alpha V in type 17-associated fibrosis, integrin-alpha V was not critical to the development of type 2-driven fibrosis. However, our studies reveal a novel mechanism through which fibroblasts, via integrin-alpha V expression, are capable of regulating immune polarization.

11:30 Targeting Integrins for Fibrosis

Scott Turner, PhD, Vice President, Translational Sciences, Pliant Therapeutics

aV integrins are a subset of a family of heterodimeric transmembrane proteins that mediate cell-cell and cell-extracellular matrix signaling. Targeting aV integrins with small molecules has been a challenge in the drug discovery field, primarily due to limited approaches to selectivity, complex signaling mechanisms, poor ADME properties and poor translation to a clinical setting. This talk will focus on our approach to addressing these concerns, leading to in vivo active molecules that translate to human disease.

12:00 pm Disease-Specific Extracellular Matrix Cell Culture Substrates to Improve Predictive in Vitro Models of NASH

John O'Neill, CSO, Xylyx Bio, Inc.

Introducing a standardized, fully humanized commercial 3D cell culture platform for fibrosis research and discussing how this platform can reduce the dependence on animal models, and enable more relevant scientific results leading to improved drug discovery process.  

12:15 Sponsored Presentation (Opportunity Available)

12:30 Transition to Lunch

12:35 Luncheon Presentation (Sponsorship Opportunity Available) or Enjoy Lunch on Your Own

1:05 Dessert and Coffee Break in the Exhibit Hall with Poster Viewing

TARGETING LIVER DISEASe

2:00 Chairperson’s Remarks

Vanessa Morales-Tirado, PhD, Senior Scientist III, Translational Immunology, Immunology Discovery, AbbVie Bioresearch Center

2:05 Progress Toward a Combination Therapy to Cure HBV

Michael Sofia, PhD, CSO, Arbutus Biopharma, Inc.

It is widely held that a combination of agents with different mechanisms of action will be required to achieve an HBV functional cure that is broad-based and of finite duration. To deliver on such an HBV curative regimen, we believe that cessation of viral replication, reduction of HBsAg levels, stopping replenishment of cccDNA pools and reactivation of the host immune response against HBV will need to be achieved. Progress toward the development of a combination therapy that addresses these key objectives will be presented.

2:35 NASH: Drug Development Landscape with a Focus on Cirrhosis

Peter Traber, MD, Partner, Alacrita Consulting; Adjunct Professor of Medicine, University of Pennsylvania School of Medicine

NASH, non-alcoholic steatohepatitis, is a chronic, slowly progressive inflammatory and fibrotic disease of the liver which progresses in some individuals to cirrhosis with its attendant complications, including death and liver transplant. In this presentation, I will review the status of drug candidates in clinical trials and their MOA (no treatments are on the market yet). Additionally, the differences in the pathophysiology and impact on patients between precirrhotic and cirrhotic NASH will be reviewed. I will also put in the context of current ongoing development programs, the acceptable and potential regulatory endpoints for clinical trials.

3:05 Targeting Galectin-3 in Fibrotic Disease

Rob Slack, PhD, Director, Pharmacology, Galecto, Inc.

Galectin-3 is β-galactoside-binding lectin highly expressed in fibrotic tissue of diverse etiologies and has been shown to play a key role in lung, liver and kidney fibrosis. Galecto, Inc. have developed a number of high affinity and selective galectin-3 inhibitors currently undergoing clinical investigation in fibrotic diseases of the lung and liver. This talk will focus on the translational pharmacology of these galectin-3 inhibitors and their potential as anti-fibrotic therapies.

3:35 Close of Conference

* 活動內容有可能不事先告知作更動及調整。

Choose your language
Chinese
Japanese
Korean
English




6月2日~4日

加速標靶發現

擴大化合物與Druggable空間

新小分子標靶

新適應症與模態

癌症免疫療法進步

疾病模型

腫瘤治療領域臨床前研究策略的模式與工具

藥物代謝與安全性測試的進步

癌症免疫療法生物標記

臨床與轉譯生物標記

新藥發現與開發的AI

6月3日~4日

新藥發現的技術


免費電子郵件通知服務